Invokana and metformin more effective treatment for type 2 diabetes, study finds
A combination therapy of metformin and Invokana is a more effective treatment for type 2 diabetes than either of the drugs independently, according to new research.
The study, which was conducted at the Dallas Diabetes and Endocrine Center at Medical City, focused on participants who had never been treated with type 2 diabetes medication before (“drug-naive” patients). The aim of the study was to assess whether the SGLT2 inhibitor Invokana (canagliflozin) could be used alongside metformin in a safe and effective manner.
Invokana plus metformin Study
The study involved data from 1,186 drug-naive participants. The mean age of the participants was 54.9 years. On average, the participants had had type 2 diabetes for 3.3 years
The participants were separated into five groups: 100mg Invokana plus metformin, 300mg Invokana plus metformin, 100mg Invokana, or 300mg canagliflozin or metformin. Over a 26-week period, the researchers observed changes to HbA1c, fasting plasma glucose and body weight.
The participants given the combination lowered their HbA1c levels more than the other groups, as well as losing more weight.
“Initial therapy with CANA plus MET was more effective and generally well tolerated versus each monotherapy in drug-naive type 2 diabetes,” the researchers wrote.
The findings are published in Diabetes Care.
Add A Comment
- We're loving Michela's tattoo <3 https://t.co/Wf02d0HT6P
- NEWS: Gastric bypass-induced type 2 diabetes remission linked to gut microorganisms: https://t.co/I3vIXBUuPM